Business Context and Reporting Period
This Form 8-K, filed on September 11, 2025, by Bausch Health Companies Inc. (BHC), reports the consummation of a previously announced acquisition of DURECT Corporation. The transaction was finalized on September 11, 2025, following the expiration of a tender offer on September 10, 2025.
Key Financial Metrics and Transaction Terms
- Acquisition Price: $1.75 per share in cash.
- Contingent Value Rights (CVRs): One non-transferrable CVR per share, entitling holders to a pro rata portion of up to $350,000,000 in aggregate milestone payments based on net sales achievements.
- Shares Tendered: 19,984,767 shares validly tendered and not withdrawn.
- Ownership Percentage: Approximately 62% of total outstanding shares as of the expiration time.
- Post-Transaction Structure: DURECT Corporation continues as a wholly-owned subsidiary of Bausch Health Americas, Inc. (BHA).
Material Changes
The primary material change is the successful completion of the tender offer and the subsequent merger. The number of shares tendered satisfied the Minimum Condition defined in the Merger Agreement. Consequently, BHC Lyon merged with and into DURECT under Section 251(h) of the Delaware General Corporation Law without a stockholder vote, making DURECT a wholly-owned subsidiary of BHA.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or specific risk factors beyond the standard contingencies associated with the transaction. The transaction includes contingent payments dependent on future net sales milestones, which represent a potential future liability subject to performance conditions. Retention bonuses payable to certain DURECT employees upon milestone achievement will be netted against the $350 million aggregate milestone payments.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding to confirm the 62% ownership stake calculation.
- Review the specific net sales milestones required to trigger the $350 million contingent value payments.
- Confirm the treatment of the remaining 38% of DURECT shares not tendered in the offer.
- Examine the attached Joint Press Release (Exhibit 99.1) for detailed management commentary on strategic rationale.